Edema Clinical Trials - Global Strategic Business Report 2026: Capture A US$1.2 Billion Market By 2032


Date:

(MENAFN- GlobeNewsWire - Nasdaq) Dublin, Nov. 20, 2026 (GLOBE NEWSWIRE) -- "Edema Clinical Trials - Global Strategic Business Report 2026" has been added to ResearchAndMarkets.com's offering.

The global edema clinical trials market was valued at US$899.7 million in 2025 and is projected to reach US$1.2 billion by 2032, expanding at a compound annual growth rate (CAGR) of 4.6%. Market growth is supported by the rising prevalence of cardiovascular, renal, hepatic, inflammatory and oncological conditions, alongside continued investment in novel therapeutics, advanced diagnostics and patient-centric clinical research models.

Edema Clinical Trials Market Trends and Growth Drivers

Edema is becoming an increasingly important endpoint in clinical studies involving heart failure, chronic kidney disease, liver disorders, autoimmune diseases, cancer and infectious conditions. Pharmaceutical and biotechnology companies are evaluating diuretics, biologics, anti-inflammatory agents, immunotherapies and personalized treatment pathways for their ability to prevent or manage fluid retention.

The growing burden of chronic disease, particularly among aging populations, is creating a larger and more diverse pool of potential clinical trial participants. Edema is also being monitored as an indicator of disease progression, treatment response and adverse drug effects, increasing its relevance across multiple therapeutic areas.

Technological innovation is transforming edema clinical trial design and execution. Wearable biosensors, connected scales and home-based bioimpedance systems support continuous monitoring of fluid levels and treatment response. High-frequency ultrasound, magnetic resonance imaging and three-dimensional body composition scanning are improving the consistency and precision of edema assessments.

Electronic data capture systems, cloud-based clinical trial platforms, artificial intelligence and machine learning are also enhancing data validation, patient stratification and adaptive decision-making. These technologies support decentralized and hybrid clinical trials, helping sponsors recruit participants from rural, homebound and historically underrepresented populations.

Regulatory expectations and patient priorities are further influencing market development. Trial protocols increasingly incorporate patient-reported outcomes, quality-of-life measures, functional assessments, biomarkers, imaging indicators and long-term follow-up. Digital diaries and mobile applications are being used to capture symptom variations, while multicenter international studies are improving representation across demographic, genetic and geographic groups.

Market Segment and Regional Outlook

The report analyzes the edema clinical trials market by phase, participant group, study design and edema type. Clinical trial phases include Phase I, Phase II, Phase III and Phase IV. Participant categories cover pediatric, adult and geriatric populations, while study designs include interventional, observational and expanded access trials. The market is also assessed across systemic and localized edema studies.

  • Phase I outlook: The Phase I edema clinical trials segment is forecast to reach US$610.1 million by 2032, growing at a CAGR of 5.6%.
  • Phase II outlook: The Phase II segment is projected to expand at a CAGR of 3.6% during the analysis period.
  • United States: The U.S. edema clinical trials market was valued at US$245.1 million in 2025.
  • China: China is forecast to grow at an 8.2% CAGR and reach US$262 million by 2032.

Geographic coverage includes the United States, Canada, Japan, China, Europe, Asia-Pacific, Latin America, the Middle East and Africa. Country-level analysis includes France, Germany, Italy, the United Kingdom, Spain, Russia, Australia, India, South Korea, Argentina, Brazil, Mexico, Iran, Israel, Saudi Arabia and the United Arab Emirates.

Strategic Value of the Edema Clinical Trials Market Report

  • Independent market analysis and annual forecasts from 2025 through 2032, presented in US$ million.
  • Detailed assessment of market trends, growth drivers, constraints and emerging revenue opportunities.
  • Segment-level analysis by clinical phase, participant population, study design and edema type.
  • Regional and country-level insights into market growth, competitive conditions and future demand.
  • Evaluation of decentralized trials, digital monitoring, advanced imaging and artificial intelligence applications.
  • Competitive intelligence covering established pharmaceutical companies, biotechnology firms and emerging market participants.
  • Complimentary report updates for one year to reflect relevant market developments.

Companies Featured in the Report

  • AbbVie Clinical Trials
  • Alimera Sciences, Inc.
  • Bayer AG
  • Biogen, Inc.
  • Chengdu Kanghong Pharmaceutical Group
  • F. Hoffmann-La Roche Ltd.
  • Frontera Therapeutics
  • GSK Plc
  • Kiora Pharmaceutical
  • Kyowa Kirin Co., Ltd.

Domain Expert Insights and Differentiators

  • Expert-led market perspective: The analysis incorporates insights from industry specialists, enterprise leaders and academic experts to provide context beyond conventional secondary research.
  • Early market signal identification: The report tracks developments emerging from expert discussions, corporate activity and market-relevant events before they are fully reflected in established research sources.
  • Validated intelligence base: Findings draw on conference sessions, keynote presentations, panel discussions, corporate disclosures, annual reports, institutional publications and other verified sources.
  • Strategic market direction: The report connects emerging signals with the forces shaping clinical trial investment, therapeutic development and competitive positioning.
  • Company intelligence: Coverage extends beyond market-level forecasts to assess organizations influencing the global edema clinical trials competitive landscape.
  • Relevant market share analysis: Competitive structures are examined across major regions where market dynamics and available evidence support meaningful comparison.

Key Questions Addressed

  • How will the global edema clinical trials market evolve through 2032?
  • Which clinical phases and study designs offer the strongest growth potential?
  • How are digital health technologies and decentralized trials changing edema research?
  • Which regional markets are expected to record the fastest expansion?
  • What regulatory, clinical and operational factors will influence market growth?
  • Which companies are shaping the competitive landscape?

The report provides decision-makers with actionable intelligence for evaluating clinical development opportunities, regional expansion strategies, technology investments and competitive positioning within the global edema clinical trials market.

Key Attributes

Report Attribute Details
No. of Pages 461
Forecast Period 2025-2032
Estimated Market Value (USD) in 2025 $899.7 Million
Forecasted Market Value (USD) by 2032 $1200 Million
Compound Annual Growth Rate 4.6%
Regions Covered Global


For more information about this report visit

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN20112026004107003653ID1111996718


GlobeNewsWire - Nasdaq

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.



More Story

Search